Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes:insights from the EXSCEL trial by Clegg, Lindsay E. et al.
  
 University of Groningen
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or
sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes
Clegg, Lindsay E.; Penland, Robert C.; Bachina, Srinivas; Boulton, David W.; Thuresson,
Marcus; Heerspink, Hiddo J. L.; Gustavson, Stephanie; Sjostrom, C. David; Ruggles, James





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., ... Holman, R.
R. (2019). Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially,
on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Cardiovascular Diabetology, 18(1), [138]. https://doi.org/10.1186/s12933-019-0942-x
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 19-05-2020
Clegg et al. Cardiovasc Diabetol          (2019) 18:138  
https://doi.org/10.1186/s12933-019-0942-x
ORIGINAL INVESTIGATION
Effects of exenatide and open-label 
SGLT2 inhibitor treatment, given in parallel 
or sequentially, on mortality and cardiovascular 
and renal outcomes in type 2 diabetes: insights 
from the EXSCEL trial
Lindsay E. Clegg1* , Robert C. Penland2, Srinivas Bachina2, David W. Boulton1, Marcus Thuresson3, 
Hiddo J. L. Heerspink4, Stephanie Gustavson5, C. David Sjöström6, James A. Ruggles7, Adrian F. Hernandez8, 
John B. Buse9, Robert J. Mentz8 and Rury R. Holman10
Abstract 
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists 
(GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. 
However, evidence on clinical outcomes in patients treated with both GLP-1 RA and SGLT2i is lacking. We aim to pro-
vide insight into the effects of open-label SGLT2i use in parallel with or shortly after once-weekly GLP-1 RA exenatide 
(EQW) on cardiorenal outcomes.
Methods: In the EXSCEL cardiovascular outcomes trial EQW arm, SGLT2i drop-in occurred in 8.7% of participants. 
These EQW+SGLT2i users were propensity-matched to: (1) placebo-arm participants not taking SGLT2i (n = 572 per 
group); and to (2) EQW-arm participants not taking SGLT2i (n = 575), based on their last measured characteristics 
before SGLT2i initiation, and equivalent study visit in comparator groups. Time-to-first major adverse cardiovascular 
event (MACE) and all-cause mortality (ACM) were compared using Cox regression analyses. eGFR slopes were quanti-
fied using mixed model repeated measurement analyses.
Results: In adjusted analyses, the risk for MACE with combination EQW+SGLT2i use was numerically lower compared 
with both placebo (adjusted hazard ratio 0.68, 95% CI 0.39–1.17) and EQW alone (0.85, 0.48–1.49). Risk of ACM was 
nominally significantly reduced compared with placebo (0.38, 0.16–0.90) and compared with EQW (0.41, 0.17–0.95). 
Combination EQW+SGLT2i use also nominally significantly improved estimated eGFR slope compared with placebo 
(+ 1.94, 95% CI 0.94–2.94 mL/min/1.73 m2/year) and EQW alone (+ 2.38, 1.40–3.35 mL/min/1.73 m2/year).
Conclusions: This post hoc analysis supports the hypothesis that combinatorial EQW and SGLT2i therapy may pro-
vide benefit on cardiovascular outcomes and mortality.
Trial registration Clinicaltrials.gov, Identifying number: NCT01144338, Date of registration: June 15, 2010.
Keywords: SGLT2 inhibitor, GLP-1 receptor agonist, Exenatide, Cardiovascular outcomes, eGFR slope, Type 2 diabetes 
mellitus, Combination therapy, Propensity score matching
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/




1 Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, 1 
MedImmune Way, Gaithersburg, MD 20878, USA
Full list of author information is available at the end of the article
Page 2 of 12Clegg et al. Cardiovasc Diabetol          (2019) 18:138 
Background
Members of both the glucagon-like peptide-1 
receptor agonist (GLP-1 RA) and sodium-glucose 
cotransporter-2 inhibitor (SGLT2i) classes of anti-
hyperglycemic drugs have demonstrated cardio- and 
reno-protective effects in cardiovascular outcomes tri-
als (CVOTs) conducted in patients with type 2 diabe-
tes mellitus. While the study populations, designs, and 
results of individual trials have varied, meta-analyses 
suggest that both classes reduce major adverse car-
diovascular events (MACE) in participants with estab-
lished atherosclerotic cardiovascular disease (ASCVD) 
[1–4]. These meta-analyses additionally show that 
SGLT2i reduce risk of hospitalization for heart failure 
and the risk of worsening estimated glomerular filtra-
tion rate (eGFR) or end-stage renal disease, regardless 
of ASCVD status [1–3].
Many patients require multiple anti-hyperglycemic 
agents to manage their diabetes. Given the largely dis-
tinct mechanisms, beyond glycemic control, through 
which GLP-1 RA and SGLT2i are hypothesized to exert 
their cardiorenal effects, there is considerable interest in 
how the combination of these two classes would effect 
long-term outcomes [5, 6]. The 104 week DURATION-8, 
24  week AWARD-10, and 30  week SUSTAIN 9 trials 
demonstrated that simultaneous initiation of GLP-1 RA 
exenatide and SGLT2i dapagliflozin, or addition of GLP-1 
RAs dulaglutide and semaglutide to open-label SGLT2i, 
durably improved glycemic control and cardiovascular 
risk factors without increasing the risk of hypoglycemia 
[7–10]. However, no clinical trial or real world evidence 
on long-term cardiovascular outcomes, mortality, and 
renal disease progression with combination GLP-1 RA 
and SGLT2i treatment have been reported to date.
The EXenatide Study of Cardiovascular Event Lowering 
(EXSCEL) was a randomized, placebo-controlled, global 
pragmatic clinical trial designed to assess the effect of 
subcutaneous once-weekly GLP-1 RA exenatide (EQW) 
2 mg on cardiovascular outcomes in 14,752 participants 
with type 2 diabetes mellitus and a range of cardiovas-
cular risk [11]. Potential participants were permitted to 
take up to three oral anti-hyperglycemic drugs, or insulin 
in combination with up to two oral anti-hyperglycemic 
agents, as part of usual care for their diabetes manage-
ment. During the course of EXSCEL, three SGLT2i were 
approved and marketed.
This posthoc analysis of EXSCEL leveraged the pool 
of participants taking open label SGLT2i in addition to 
study drug to quantify the impact of this EQW+SGLT2i 
combination on cardiorenal outcomes, as compared with 
both: (1) treatment with neither EQW nor an SGLT2i, 
and (2) treatment with EQW but not an SGLT2i, on top 
of standard of care.
Methods
Population and SGLT2i usage
EXSCEL (NCT01144338) enrolled 14,752 patients in 35 
countries between June 2010 and September 2015. The 
primary results, study design and baseline characteristics 
have been published [11–13]. Briefly, inclusion criteria 
included a hemoglobin A1c  (HbA1c) of 6.5% to 10%, and 
any level of cardiovascular risk, targeting ~ 70% of partic-
ipants with a previous cardiovascular event. Participants 
were excluded if they were < 18 years old, had type 1 dia-
betes, ≥ 2 episodes of severe hypoglycemia in the previ-
ous 12  months, an estimated glomerular filtration rate 
(eGFR) < 30 mL/min/1.73 m2, or previous pancreatitis.
All EXSCEL participants were included in this analysis 
except for 786 placebo arm participants that took open-
label SGLT2i. The 33 EXSCEL participants who never 
received study drug and a further 635 participants miss-
ing required covariates were excluded from propensity 
matching (Additional file 1: Figure S1).
Information on SGLT2i use was collected at each 
6-monthly study visit [11]. As precise dates for concomi-
tant medication initiation and cessation were not item-
ized, we assumed SGLT2i initiation at the first study 
visit that recorded its use [14]. SGLT2i exposure time 
was calculated as the interval from the first visit with 
known usage to the last study visit with SGLT2i use 
recorded, regardless of gaps or switching of SGLT2i type. 
No lower bound on exposure was imposed. We assumed 
no SGLT2i use when information was missing; SGLT2i 
usage data was not collected before May 2013, 6 months 
after the first market approval of an SGLT2i. Due to the 
limited size of the available data, subjects were eligible 
for inclusion in the EQW+SGLT2i cohorts whether they 
discontinued study drug before SGLT2i initiation or not.
Endpoints
This posthoc analysis examined multiple prespecified 
time-to-event EXSCEL endpoints: (1) first adjudicated 
composite of a three-point major adverse cardiovascular 
event (MACE), defined as cardiovascular death, nonfa-
tal myocardial infarction or nonfatal stroke, the primary 
endpoint of the trial; (2) all-cause mortality (ACM); (3) 
cardiovascular death; and (4) serious hypoglycemia, 
defined as hypoglycemia requiring third-party assistance. 
Change over time in MDRD eGFR was examined to 
quantify renal disease progression. Exploratory time-to-
event analyses were performed for: (1) hospitalization for 
heart failure (hHF); (2) a composite of hospitalization for 
heart failure and cardiovascular death; (3) nonfatal myo-
cardial infarction; (4) nonfatal stroke; (5) a composite of a 
persistent 40% reduction in eGFR, renal dialysis, or renal 
transplant (“Renal_1”), (6) a composite of Renal_1 plus 
new macroalbuminuria (“Renal_2”); and (7) amputation.
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Propensity matching
Propensity matching was performed using the same 
protocol as outlined in [14], designed to balance medi-
cal history, demographics, laboratory measurements, 
medication use, and follow-up time. Participants tak-
ing SGLT2i in the EQW arm were matched at the first 
known SGLT2i use to: (1) participants in the placebo 
arm that did not take SGLT2i (“Placebo comparison”); 
and (2) participants in the EQW arm that did not take 
SGLT2i (“Exenatide comparison”), based on covariates at 
the comparable study visit. No comparison was made to 
placebo+SGLT2i users because a large comparator group 
is necessary to achieve a well-matched set of cohorts, and 
both the EQW+SGLT2i and placebo+SGLT2i groups 
in EXSCEL were moderately-sized. Matching was per-
formed first for the baseline visit, and then subsequently 
for each study visit without replacement of participants 
already matched. Propensity scores were calculated 
across all available participants and visits using a gen-
eralized linear model, and matching was performed via 
the nearest neighbor approach, using this score and logit 
distance calculated at each visit. A caliper of 0.1 and a 
1:1 matching ratio were used in the R package MatchIt 
[15]. A matched set of cohorts were accepted if the post-
matching difference between treatment groups for every 
covariate was less than 0.1 standardized difference.
The nearest neighbor approach matches participants 
in a random order, resulting in changes to the cohorts if 
matching is repeated. To prevent selection bias, the first 
set of cohorts generated that met the acceptance criteria 
were selected for this analysis. To assess the robustness of 
the results to variability in matching, we repeated match-
ing 5000 times for each comparison, and compared the 
distributions of estimated hazard ratios in the accepted 
cohorts to those in the primary analysis. We also gener-
ated cohorts matched to only subjects taking exenatide 
and SGLT2i simultaneously, and performed a sensitivity 
analysis where we censored subjects in the primary anal-
ysis at initiation of open-label GLP-1 RA (in violation of 
study protocol) to further probe the impact of variation 
in drug usage patterns within our cohorts.
Covariates used for propensity matching were: age, 
sex, ethnicity, smoking status (trial baseline), race, 
region, duration of diabetes, history of heart failure, his-
tory of prior cardiovascular disease (CVD), microalbu-
minuria, macroalbuminuria, BMI, eGFR, systolic blood 
pressure,  HbA1c, total cholesterol, and use of renin-angi-
otensin-aldosterone system inhibitors, thiazolidinedi-
ones, metformin, dipeptidyl peptidase-4 inhibitors, and 
insulin. All covariates were evaluated based on the last 
information prior to the first known SGLT2i usage (or 
comparable visit in controls). For participants on SGLT2i 
prior to enrollment, baseline characteristics were used. 
Prior CVD was defined, per EXSCEL protocol, as major 
clinical manifestations of coronary artery disease, ath-
erosclerotic peripheral artery disease, or ischemic cere-
brovascular disease, and was updated from trial baseline 
status based on recorded incidence of MACE, periph-
eral artery or vascular disease, coronary catheterization, 
angioplasty or stenting, coronary artery bypass, or per-
cutaneous coronary intervention. Similarly, history of 
heart failure, age, and duration of diabetes were updated 
from trial baseline to reflect recorded hHF and time in 
trial, respectively.
As EXSCEL collected only local laboratory measure-
ments, non-physiologically-reasonable outliers were capped 
prior to matching using the following cut-offs: BMI > 60 kg/
m2, eGFR > 250 mL/min/1.73 m2,  HbA1c > 15% (140 mmol/
mol), and total cholesterol > 15 mmol/L. These cutoffs were 
set prior to analysis based on expected physiological ranges, 
and we confirmed that only a small number of all trial meas-
urements were capped: 164 BMI (0.2%), 20 eGFR (0.02%), 
49  HbA1c (0.06%), and 15 cholesterol (0.02%).
Time‑to‑event analyses
Hazard ratios (HR) for time-to-first-event analyses in 
both sets of propensity-matched cohorts were calculated 
via Cox proportional hazards regression. Analyses were 
performed with treatment as the sole exploratory vari-
able (unadjusted), and adjusted for: duration of diabetes, 
age, sex, history of CVD, prior heart failure, prior micro-
albuminuria, prior macroalbuminuria, eGFR, and  HbA1c, 
to provide a “doubly robust” estimator with lower risk of 
bias than would be obtained via propensity matching or 
adjustment alone [16]. The number of adjustment covari-
ates was constrained because of the limited size of the 
matched cohorts [17].
Follow-up time began at matching (SGLT2i initia-
tion or equivalent study visit in controls), and continued 
until the end of trial follow-up, regardless of study drug 
or SGLT2i discontinuation. Participants with an event 
before matching were censored at time zero for analysis 
of that endpoint. For composite endpoints, censoring 
occurred at the last information on the earliest censored 
component. For the renal composites, renal dialysis or 
transplant events occurring within 30  days of the last 
eGFR measurement were included.
Only participants with at least two post-matching 
eGFR measurements were included in renal time-to-
event analyses (Additional file  1: Table  S3). Persistent 
40% eGFR reduction was defined as two sequential 
post-matching eGFR measurements ≤ 60% of the last 
pre-match eGFR measurement, with eGFR values over 
250  mL/min/1.73  m2 excluded. eGFR was calculated 
centrally using the MDRD formula, based on local, site-
reported serum creatinine measurements [18].
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Endpoints were analyzed in both comparisons, but 
no direct comparisons were made between the two 
sets of matched cohorts. Owing to the posthoc nature 
of this analysis, all reported p-values are nominal and 
no multiple test corrections were performed. A p-value 
< 0.05 was considered nominally significant.
eGFR slope
eGFR slope vs. time was analyzed in both sets of 
propensity-matched cohorts using a mixed-model 
repeated measures (MMRM) analysis to estimate the 
overall treatment effect on eGFR slope. MDRD-based 
eGFR was the dependent variable, with time (sched-
uled visit window) and baseline eGFR as linear covari-
ates, treatment arm and visit-by-treatment interaction 
as fixed effects, and patient as a random effect.
Software
Data was prepared in SAS 9.4, and all analyses were 
performed in R version 3.4.0 [19].
Results
Full population characteristics and drug use
During the course of EXSCEL, 645 EQW arm participants 
used an SGLT2i at some point, with the highest SGLT2i 
use in Western Europe and North America (Fig. 1a). Com-
pared with non-SGLT2i users, these participants were 
more likely to be male (68% vs 61%), white (84% vs. 75%), 
have less history of CV disease (62% vs. 74%) and heart 
failure (9.1% vs. 17%) at trial baseline, and have more 
history of albuminuria (23% vs. 16%) (Additional file  1: 
Table S2) [12]. This group also had higher HbA1c (8.3% vs. 
8.1% (67 mmol/mol vs. 65 mmol/mol)) and eGFR (85 vs. 
76  mL/min/1.73  m2), and took more anti-hyperglycemic 
agents aside from GLP-1 RA and SGLT2i (1.7 vs. 1.3) than 
non-SGLT2i users in EXSCEL (Additional file 1: Table S2).
Of the three SGLT2i taken by EXSCEL participants, 
dapagliflozin was the most commonly used (Additional 
file 1: Table S1). Median time of first known SGLT2i use 
in the EQW arm was 2.7 years (interquartile range (IQR) 
1.5–3.8 years) (Additional file 1: Figure S2A), and median 
time from first to last known SGLT2i use was 9.3 months 
(IQR 2.5–18.1 months) (Fig. 1b).
Fig. 1 SGLT2i usage in EXSCEL. a Percentage of exenatide arm participants taking SGLT2i at some point, by drug and by region. “Multiple” indicates 
use of more than one SGLT2i during the trial. b Histogram of time from first to last known SGLT2i use in the EXSCEL exenatide QW (light gray) and 
placebo (dark gray) arms. Note that, given lack of precise start/stop dates, this estimate of length of SGLT2i exposure represents a lower bound. 
c, d Time of SGLT2i initiation or matching relative to discontinuation of EQW or placebo in the propensity-matched cohorts. Blue: combination 
EQW+SGLT2i cohort; green: placebo cohort; red: EQW cohort
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Propensity matching
Of the 623 SGLT2i users in the EQW arm with all 
required covariates (Additional file  1: Figure S1), 572 
were matched in the placebo comparison (92%), and 
575 were matched in the EQW comparison (92%), with 
all covariates having an imbalance of less than 0.1 stand-
ardized difference in the accepted sets of cohorts Addi-
tional file 1: Figures S3A, B), and similar propensity score 
distributions between cohorts (Additional file  1: Figure 
S4). These cohorts (Table  1) were generally similar to 
the overall distribution of SGLT2i users in the EQW arm 
(Additional file 1: Table S2), though, importantly, differ-
ent than the overall population of EXSCEL [12]. 560 of 
the participants in the EQW+SGLT2i cohorts were iden-
tical between the two comparisons. Characteristics in the 
separately matched “placebo” and “EQW” comparator 
cohorts were generally similar, but subjects in the “EQW” 
cohort were older, had a longer duration of diabetes, and 
were less likely to be Hispanic (Additional file  1: Figure 
S3C), limiting validity of direct comparisons between 
these groups. Median follow-up time for ACM in the 
placebo comparison was 13.3 months (IQR 6.5–23.1) for 
the combination cohort and 14.2 months (IQR 4.5–27.0) 
for the placebo cohort. In the EQW comparison, median 
follow-up was 13.3  months (IQR 6.5–23.0) in the com-
bination cohort and 15.1  months (IQR 6.0–26.7) in the 
exenatide cohort.
Median study drug exposure (from trial baseline) in 
the propensity-matched cohorts ranged from 29.7 to 
38.4  months (Additional file  1: Figure S2C, D). Median 
time from first to last known SGLT2i use was 9.8 months 
(IQR 3.1–18.8) in both comparisons. Median time from 
SGLT2i initiation/matching to study drug discontinu-
ation in the placebo comparison was 3.2  months [IQR 
from 12.2  months before matching to 14.8  months 
after matching] in the placebo cohort and 4.7  months 
[9.7  months before to 14.8  months after] in the combi-
nation cohort (Fig.  1c). In the exenatide comparison, 
median time from SGLT2i initiation/matching to study 
drug discontinuation was 5.6  months [IQR 7.9  months 
before to 19.0  months after] in the EQW cohort and 
4.9 months [IQR 9.2 months before to 14.8 months after] 
in the combination cohort (Fig. 1d). In total, 344 out of 
572 participants (60%) in the placebo comparison and 
348 of 575 participants (61%) in the EQW comparison 
started SGLT2i before EQW discontinuation.
Time‑to‑event analyses
Cox proportional hazard models were used to estimate 
hazard ratios for MACE, ACM, CV death, and seri-
ous hypoglycemia in each of the two sets of cohorts. 
In both comparisons, the hazard ratio for MACE 
with EQW+SGLT2i was non-significantly decreased 
compared with placebo (adjusted HR (95% CI) 0.68 (0.39–
1.17)), and compared with EQW (0.85 (0.48–1.49), Fig. 2). 
This reduction was driven by a nominally significant 
decrease in risk of CV death (aHR 0.17 (0.04–0.77) com-
pared with placebo and 0.21 (0.05–0.93) compared with 
EQW); nonfatal MI and nonfatal stroke were unchanged 
(Additional file 1: Tables S3 and S4). All-cause mortality 
was also reduced (aHR vs. placebo of 0.38 (0.16–0.90) and 
vs. EQW of 0.41 (0.17–0.95)), with no increase in risk of 
serious hypoglycemia (Fig.  2). Kaplan–Meier curves are 
shown in Additional file 1: Figures S5–S9.
In the exploratory analysis, the composite of hHF and 
CV death was nominally significantly reduced in both 
comparisons (Additional file 1: Tables S3 and S4), driven 
by CV death, while hHF was not reduced. Event numbers 
were small for both renal composites, with non-signif-
icant reductions in the estimated hazard ratios (Addi-
tional file 1: Tables S3 and S4). Amputations were rare (5 
events total) and not significantly different in either com-
parison (Additional file 1: Tables S3 and S4).
In the nearest neighbor method, re-matching changes 
the composition of the comparator cohorts, and the 
resultant event rates. To account for this random effect, 
we repeated the propensity matching procedure 5000 
times, generating approximately 2000 accepted sets of 
cohorts for each comparison. Comparing the distribu-
tions of hazard ratio estimates in these sets to the pri-
mary case reported here confirms that those for MACE, 
ACM, and CV death are near the centers of the respec-
tive distributions (Additional file 1: Figure S10A, B). The 
estimate for hHF in the placebo comparison is higher 
than most estimates, likely due to random chance and 
low event numbers (Additional file 1: Figure S10C), with 
most runs suggesting a numerically lower hHF risk with 
EQW+SGLT2i in both comparisons.
Next, we asked whether the observed effects were simi-
lar in only subjects taking EQW and SGLT2i simultane-
ously. In these smaller cohorts (n = 336–340 per cohort), 
no MACE benefit was observed, but trends for reduced 
ACM and CV death were consistent with the primary 
analysis (Additional file  1: Tables S5 and S6). Addition-
ally, censoring of subjects initiating open-label GLP-1 RA 
had very little impact on estimated hazard ratios (Addi-
tional file 1: Tables S7 and S8).
eGFR slope
Figure  3 shows geometric mean eGFR over time after 
matching in the two sets of propensity-matched cohorts. 
MMRM-estimated slopes in the placebo comparison 
were + 1.21 mL/min/1.73 m2/year (se 0.37) in the combi-
nation cohort and − 0.71 mL/min/1.73 m2/year (se 0.33) 
in the placebo cohort, resulting in an estimated treatment 
effect of + 1.94 mL/min/1.73 m2/year (95% CI 0.94–2.94, 
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Table 1 Clinical characteristics of propensity-matched cohorts at time of matching
Placebo comparison Exenatide comparison
Placebo,
No SGLT2i







Participants, n 572 572 575 575
Sex, male 380 (66%) 391 (68%) 399 (69%) 395 (69%)
Age, years 62 (10) 62 (9) 63 (10) 62 (9)
Race
 White 486 (85%) 487 (85%) 495 (86%) 488 (85%)
 Black 14 (2.4%) 20 (3.5%) 24 (4.2%) 22 (3.8%)
 Asian 52 (9.1%) 50 (8.7%) 44 (7.7%) 50 (8.7%)
 Other/unknown 20 (3.5%) 15 (2.6%) 12 (2.1%) 15 (2.6%)
Region
 North America 213 (37%) 212 (37%) 210 (37%) 215 (38%)
 Latin America 27 (4.7%) 27 (4.7%) 25 (4.3%) 26 (4.5%)
 Asia Pacific 53 (9.3%) 54 (9.4%) 50 (8.7%) 54 (9.4%)
 Western Europe 200 (35%) 182 (32%) 190 (33%) 186 (32%)
 Eastern Europe 79 (14%) 97 (17%) 100 (17%) 94 (16%)
Ethnicity, Hispanic 47 (8.2%) 33 (5.8%) 32 (5.6%) 33 (5.7%)
Duration of diabetes, years 16 (8) 16 (8) 17 (9) 16 (8)
History of CVD (CAD, PAD, or stroke) 377 (66%) 379 (66%) 395 (69%) 378 (66%)
History of heart failure 64 (11%) 62 (11%) 65 (11%) 63 (11%)
History of retinopathy 99 (17%) 108 (19%) 108 (19%) 109 (19%)
History of micro- or macro-albuminuria 172 (30%) 159 (28%) 164 (29%) 160 (28%)
 Microalbuminuria 147 (26%) 139 (24%) 134 (23%) 140 (24%)
 Macroalbuminuria 31 (5.4%) 28 (4.9%) 34 (5.9%) 28 (4.9%)
Systolic blood pressure, mmHg 133.6 (16.2) 133.4 (15.4) 133.1 (15.7) 133.4 (15.5)
Diastolic blood pressure, mmHg 76.6 (10.4) 77.5 (10.0) 77.3 (10.1) 77.5 (10.0)
BMI, kg/m2 33.9 (6.9) 34.1 (6.3) 34.1 (6.5) 34.1 (6.3)
HbA1c, % 8.3 (1.5) 8.2 (1.2) 8.2 (1.6) 8.2 (1.2)
Cholesterol, mmol/L 4.2 (1.2) 4.2 (1.2) 4.2 (1.2) 4.2 (1.2)
 LDL, mmol/L 2.3 (1.0) 2.2 (1.0) 2.2 (0.9) 2.2 (1.0)
 HDL, mmol/L 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3)
UACR (median, IQR), g/mol 2.2 [0.9,6.6] 1.4 [0.5,4.4] 1.9 [0.6,5.0] 1.4 [0.5,4.2]
Hemoglobin, g/L 137.3 (15.6) 140.2 (16.3) 137.0 (15.4) 140.1 (16.4)
eGFR, mL/min/1.73 m2 79.7 (26.4) 81.1 (22.0) 79.6 (25.8) 81.1 (22.2)
eGFR<60 mL/min/1.73 m2 130 (23%) 93 (16%) 132 (23%) 94 (16%)
eGFR<45 mL/min/1.73 m2 46 (8.0%) 18 (3.1%) 42 (7.3%) 19 (3.3%)
Smoking
 Never 83 (15%) 77 (13%) 67 (12%) 75 (13%)
 Past 234 (41%) 231 (40%) 258 (45%) 235 (41%)
 Current 255 (45%) 264 (46%) 250 (43%) 265 (46%)
Classes of diabetes medications (n)a 1.6 (0.9) 1.5 (0.9) 1.5 (0.9) 1.5 (0.9)
RAASi 458 (80%) 461 (81%) 471 (82%) 463 (81%)
Other antihypertensives 325 (57%) 353 (62%) 336 (58%) 353 (61%)
Statins 434 (76%) 460 (80%) 433 (75%) 462 (80%)
Diuretics 247 (43%) 240 (42%) 266 (46%) 238 (41%)
Insulin 312 (55%) 324 (57%) 321 (56%) 323 (56%)
Metformin 472 (83%) 482 (84%) 480 (83%) 481 (84%)
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Table 1 (continued)
Placebo comparison Exenatide comparison
Placebo,
No SGLT2i







TZD 22 (3.8%) 29 (5.1%) 31 (5.4%) 32 (5.6%)
DPP-4i 192 (34%) 176 (31%) 186 (32%) 172 (30%)
Sulfonylureas 215 (38%) 190 (33%) 182 (32%) 189 (33%)
Continuous metrics are reported as mean (SD). Categorical metrics are reported as n (%)
BMI body mass index, CAD coronary artery disease, CVD cardiovascular disease, DPP-4i dipeptidyl peptidase-4 inhibitors, eGFR estimated glomerular filtration rate, 
GLP1-RA glucagon-like peptide-1 receptor agonists, HbA1c glycated hemoglobin, HDL high-density lipoproteins, LDL low-density lipoproteins, PAD peripheral artery 
disease, RAASi renin-angiotensin-aldosterone system inhibitors, SD standard deviation, SGLT2i sodium-glucose co-transporter-2 inhibitors, TZD thiazolidinediones, 
UACR urinary albumin-to-creatine ratio
a Classes of anti-hyperglycemic agents included: biguanides, sulfonylureas, meglitinides, DPP-4i, and TZD. Insulin, SGLT2i, and GLP1-RA (excluded by study protocol) 
are not included
Fig. 2 Cardiovascular, mortality, and safety outcomes with combination exenatide QW+SGLT2i in the propensity-matched cohorts. Additional 
details are found in Additional file 1: Tables S3, S4, and Kaplan–Meier curves in Additional file 1: Figures S5–S9. Hazard ratio adjusted for age, duration 
of diabetes, prior cardiovascular disease, heart failure, sex, microalbuminuria, macroalbuminuria, eGFR, and HbA1c, all evaluated at first known 
SGLT2i usage or equivalent visit in comparator groups. MACE: major adverse cardiovascular events; CV: cardiovascular; pt-yrs: participant-years
Fig. 3 Geometric mean (+/− standard error) eGFR in the propensity-matched cohorts. a Placebo comparison. b Exenatide comparison. Time 
zero is the time of first visit with known SGLT2i use/matching. The small differences in eGFR at matching (t=0) also reflect restrictions on SGLT2i 
use in moderate renal impairment. eGFR slopes prior to matching are shown in Additional file 1: Figure S11. Blue: combination exenatide + SGLT2i 
cohorts; green: placebo cohort; red: exenatide cohort. eGFR, estimated glomerular filtration rate; SGLT2i, sodium-glucose co-transporter-2 inhibitor
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p < 0.001). Similarly, in the EQW comparison, the esti-
mated slope was + 1.27  mL/min/1.73  m2/year (se 0.38) 
in the combination cohort, and − 1.11 mL/min/1.73 m2/
year (se 0.32) in the EQW cohort, giving an estimated 
treatment effect of + 2.38 mL/min/1.73 m2/year (95% CI 
1.40–3.35, p < 0.001).
Discussion
This analysis provides the first clinical support for the 
hypothesis that combinatorial use of GLP-1 RA and 
SGLT2i therapies may provide additional benefit on adju-
dicated cardiovascular outcomes, mortality, and renal 
disease progression, compared with GLP-1 RA without 
SGLT2i, and to standard of care with neither GLP-1 RA 
nor SGLT2i (Table  2). The subset of EXSCEL partici-
pants using SGLT2i provide a modestly-sized but cred-
ible cohort with rigorously collected clinical outcomes. 
Our analysis demonstrated numerically lower MACE 
risk, driven by a nominally significant reduction in car-
diovascular death, compared with both EQW alone and 
placebo. The reduction in ACM was also nominally sig-
nificant in both comparisons, as was the improvement in 
eGFR slope, with no increase in risk of serious hypogly-
cemia. We did not have enough data to probe the con-
tributions of each drug to the observed outcomes, or 
to compare to SGLT2i alone, and imbalances between 
the EQW alone and placebo cohorts warrant caution in 
comparing the two sets of cohorts side-by-side. None-
theless, the trend across cardiovascular and mortality 
outcomes for a numerically larger risk reduction com-
pared with placebo than compared with exenatide sup-
ports possible beneficial contributions from both drug 
classes. Conversely, the similar improvement in eGFR 
slope in both comparisons in our population suggests the 
observed eGFR slope improvement may be due primar-
ily to SGLT2i contributions when used on top of GLP-1 
RA, consistent with previous GLP-1 RA studies generally 
showing an effect more so on macroalbuminuria than on 
eGFR-based endpoints [4].
In the full EXSCEL trial, the hazard ratio for MACE 
with EQW treatment was 0.91 (95% CI 0.83–1.00) [11], 
while several meta-analyses of the GLP-1 RA class esti-
mated MACE hazard ratios from 0.87 to 0.90 [2–4, 20] 
for the class as a whole, with moderate evidence for intra-
class heterogeneity. All three components of the MACE 
composite—cardiovascular death, non-fatal MI, and non-
fatal stroke—appear to contribute to this outcome for the 
GLP-1 RA class [2, 3, 20]. While the majority of evidence 
supports this MACE benefit in subjects with ASCVD, 
there is some evidence that this benefit may extend to 
high-risk subjects without a previous CV event [4, 21]. 
In EXSCEL, the secondary end-point of ACM, while not 
formally tested due to the hierarchical nature of the sta-
tistical analysis plan, was nominally improved by EQW 
treatment (HR 0.86 (0.77–0.97) [13]. Meta-analyses sug-
gest this mortality benefit is a class effect (hazard ratios 
0.88–0.89) [4, 20], while no significant benefit on hHF or 
occurrence of serious hypoglycemia has been observed 
for the GLP-1 RA class [2, 3, 20]. In general GLP-1 RA 
trials point to a strong effect on new persistent mac-
roalbuminuria [22–24], but there is limited evidence of 
improvement on eGFR-based endpoints: sustained eGFR 
decline of 40–50% for dulaglutide [23], and a small reduc-
tion in eGFR decline with liraglutide and dulaglutude in 
participants with moderate-to-severe CKD.
Trial design and study populations also varied across 
the SGLT2i class, with MACE hazard ratios in CVOTs 
of 0.86 to 0.93 [25–27]. Again, meta-analyses suggest 
a class effect benefit of 11–12% [1, 2], with this benefit 
restricted to a 14% improvement in participants with 
existing ASCVD [1]. SGLT2i appeared to have the larg-
est benefit on the CV death component of MACE (HR 
0.84 (0.75–0.94)) [2], and consistently reduce the risk of 
hHF (HR 0.65 to 0.73) [25–27] without increasing the 
risk of hypoglycemia. ACM was significantly reduced in 
only one SGLT2i CVOT to date [27], though there was 
a trend for benefit in all three completed trials [25, 26]. 
SGLT2i also consistently improved renal outcomes, with 
Table 2 Summary of key results
Previous knowledge in the field
Multiple GLP-1 RA and SGLT2i demonstrated benefit on cardiovascular outcomes, mortality, and/or renal disease progression
The mechanisms underlying these effects, while not fully understood, are largely distinct
Combination GLP-1 RA and SGLT2i treatment improves metabolic parameters and cardiovascular risk factors, but no data on cardiovascular events, 
mortality, or renal function decline is available
New insights from this study
Combination exenatide QW and SGLT2i numerically lowered the hazard ratio for MACE, driven by a significant reduction in cardiovascular death com-
pared to exenatide alone or neither drug class
All-cause mortality risk decreased with the combination, compared to exenatide QW alone or placebo
SGLT2i-mediated eGFR slope improvement was consistent on top of placebo or exenatide QW treatment
This data supports the hypothesis that combination GLP-1 RA and SGLT2i may provide additional cardiovascular and mortality benefit to GLP-1 RA 
alone, without any increase in risk of hypoglycemia
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an estimated class benefit on worsening eGFR, ESRD, 
or renal death (HR 0.55 (0.48–0.64) [2]), regardless of 
ASCVD status and potentially also kidney disease status 
[1, 28]. In CREDENCE, canagliflozin reduced the relative 
risk of end-stage kidney disease, doubling of serum cre-
atinine, or death from renal causes by 34%, and the rela-
tive risk of end-stage kidney disease by 32% in patients 
with type 2 diabetes [29].
These differences in outcomes with GLP-1 RA and 
SGLT2i are most likely tied to their mechanisms of action, 
over and above improvement of glycemia. GLP-1 RA 
enhance insulin secretion and inhibit glucagon secre-
tion in a glucose-dependent manner, reduce appetite and 
gastric motility, increase heart rate, and exert natriuretic 
and vasodilatory effects in the kidney, contributing to 
weight loss and small blood pressure reductions [30, 31]. 
Effects on inflammation and endothelial function have 
also been observed in animals [31, 32], although clinical 
benefit of short-term exenatide treatment, compared to 
insulin glargine, on left ventricular function has not been 
observed [33]. SGLT2i act in an insulin-independent but 
glucose-dependent manner to increase urinary excre-
tion of glucose, sodium, and water via osmotic diuresis 
[34–36]. These hemodynamic effects are subsequently 
hypothesized to reduce weight, blood pressure, and extra-
cellular fluid via mechanisms distinct from and potentially 
complementary to renin-angiotensin-aldosterone system 
inhibitors [37]. SGLT2i also indirectly increase glucagon 
secretion and are hypothesized to alter inflammation, car-
diac energetics, and metabolism [34–36]. These potentially 
complementary sets of mechanisms support the hypoth-
esis that combination GLP-1 RA and SGLT2i treatment 
may results in further CV and renal benefit than observed 
with either class alone [5, 38, 39]. Results of the AWARD-
10, SUSTAIN 9, and DURATION-8 trials and a subgroup 
analysis from CANVAS showed improvement in weight, 
triglycerides, and systolic blood pressure with different 
combinations of GLP-1 RA and SGLT2i, further increasing 
interest in this key question [8–10, 40, 41]; two additional 
trials are ongoing (LIRA-ADD2SGLT2i NCT02964247 
and PIONEER4 NCT02863419). The results presented 
here support a potential added benefit for the combina-
tion of EQW and SGLT2i on ACM, at a minimum, an end-
point on which both classes alone have shown some effect, 
and which may reflect a convergence of multiple mecha-
nisms of action by these two drug classes. However, this 
analysis does not examine whether similar results would 
be observed with another GLP-1 RA.
The results in this analysis apply to a population with 
characteristics similar to the subpopulation in EXSCEL 
adding an SGLT2i as part of their usual glycemic care, as 
would be the case in a real-world analysis, and different 
from the populations typically found in a full randomized 
trial. More laboratory measurements were available here 
than are commonly found in registry data, allowing pro-
pensity matching based on these metrics and study visit. 
This approach avoids the time lag bias that can occur 
when comparing to participants initiating an anti-hyper-
glycemic medication that may be used as a different line of 
therapy [42]. Additionally, matching at comparable study 
visits avoids immortal time bias; subjects must remain 
in the trial for the same amount of time to be included, 
regardless of SGLT2i use [42]. Most participants in this 
analysis initiated EQW prior to an SGLT2i, in contrast to 
the GLP-1 RA + SGLT2i clinical trials performed to date 
[8–10, 40]. The propensity-matched cohorts also reflect 
regional patterns in SGLT2i use, with less history of CV 
disease but more albuminuria and a longer duration of 
diabetes than the overall EXSCEL trial population. Event 
rates were generally similar in these cohorts compared to 
the trial as a whole: 3.7 vs. 4.0 MACE per 100 participant-
years, 2.0 vs. 2.3 ACM per 100 participant years, and 1.4 
vs. 1.5 CV deaths per 100 participant-years in the EQW 
and placebo arms of EXSCEL, respectively [13]. These 
similarities in event rates are reassuring, though further 
study is required to assess the applicability of these results 
beyond the analyzed cohorts.
It is critical to consider the limitations of this analy-
sis when interpreting the results. The posthoc nature of 
this analysis and the moderate sizes of the propensity-
matched cohorts limit the statistical significance of our 
results; interpretation should focus on key, hypothe-
sis-generating trends, and how they compare to exist-
ing knowledge in the field. While we carefully designed 
the propensity-matching procedure to balance patient 
characteristics, including metrics of disease state, medi-
cal history, laboratory measurements, and concomitant 
medications, we cannot exclude the possibility of bias 
due to unmeasured confounders [42–44]. Median fol-
low-up time after SGLT2i initiation was under 2  years, 
restricting insight on CV outcomes and renal disease 
progression to this time-scale, which is relatively short 
for accrual of hard renal outcomes in this population with 
preserved renal function. We performed multiple analy-
ses in two different cohorts, increasing the likelihood 
of type 1 error. To confirm the robustness of our results 
to matching variability within the study population, we 
re-matched and re-estimating hazard ratios; while one 
estimate for hHF was high relative to the resulting distri-
bution (and thus likely a type 1 error), the estimates for 
MACE, ACM, and CV death were consistent with the 
overall distributions.
In EXSCEL, exact dates of SGLT2i initiation and ces-
sation were not known [11]. As such, we used an “intent-
to-treat”-like analysis, starting follow-up at the first 
known SGLT2i usage, as done previously [14]. In these 
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cohorts, some patients added SGLT2i to their treatment 
plan while still taking study drug (exenatide or placebo), 
while others discontinued study drug (but remained in 
the trial) prior to SGLT2i initiation. This mix of partici-
pants, some using EQW and SGLT2i in sequence and 
others in parallel, is reflective of individual treatment 
decisions in clinical practice [45, 46]. In only subjects 
with overlapping EQW and SGLT2i use, we saw a simi-
lar benefit on mortality as in the primary analysis, though 
not on MACE. However, the limited size and resolution 
of this dataset constrains our ability to draw conclusions 
about sequential vs. parallel use of these drugs.
Conclusions
This analysis provides the first insight, from a credible 
cohort with adjudicated CV events, into long-term car-
diorenal outcomes in subjects using EQW and SGLT2i 
either in parallel or relatively close sequence. The results, 
supporting the hypothesis that this combination may 
provide additional benefit particularly on mortality, 
motivate additional, more comprehensive study of com-
bination GLP-1 RA and SGLT2i in the future.
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